{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:44:27Z","timestamp":1761489867887,"version":"build-2065373602"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Drug\u2010induced parkinsonism is a well\u2010known complication of several different drugs\u2014the most common being neuroleptic\u2010induced parkinsonism. However, very few autopsies have been reported in such cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients assessed at Movement Disorders Clinic Saskatchewan are offered brain autopsy. Detailed clinical records are kept.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Brains were obtained from 7 drug\u2010induced parkinsonism patients with parkinsonian symptom onset coinciding with use of drugs known to produce parkinsonism. Six were on antipsychotics and 1 was on metoclopramide. Three cases were treated with levodopa for parkinsonism. In two cases, parkinsonian features reversed after stopping the offending agent. Both had autopsy evidence of preclinical PD. In 4 of the remaining 5, dopamine\u2010blocking drugs were continued until death. In 4 of those 5, brain histology revealed no cause for the parkinsonism, but 1 had mild SN neuronal loss without Lewy bodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study shows that reversal of parkinsonism after discontinuing offending drugs does not indicate absence of underlying pathology. Neuroleptics can unmask preclinical PD in patients with insufficient SN damage for the disease to manifest clinically. Though the mechanism of sustained parkinsonian features after discontinuing neuroleptics remains to be established, it is unlikely that dopamine receptor block leads to retrograde SN neuronal degeneration. Furthermore, <jats:sc>l<\/jats:sc>\u2010dopa does not appear to be toxic to SN. \u00a9 2015 International Parkinson and Movement Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.26467","type":"journal-article","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T06:54:55Z","timestamp":1449816895000},"page":"360-365","source":"Crossref","is-referenced-by-count":44,"title":["Neuroleptic\u2010induced <scp>P<\/scp>arkinsonism: <scp>C<\/scp>linicopathological study"],"prefix":"10.1002","volume":"31","author":[{"given":"Umar A.","family":"Shuaib","sequence":"first","affiliation":[{"name":"Saskatchewan Movement Disorders Program Royal University Hospital Saskatoon Saskatchewan Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H.","family":"Rajput","sequence":"additional","affiliation":[{"name":"Division of Neurology, Saskatchewan Movement Disorders Program University of Saskatchewan, Saskatoon Health Region Saskatoon Saskatchewan Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Neuropathology, Department of Pathology University of Saskatchewan, Saskatoon Health Region Saskatoon Saskatchewan Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Rajput","sequence":"additional","affiliation":[{"name":"Division of Neurology, Saskatchewan Movement Disorders Program University of Saskatchewan, Saskatoon Health Region Saskatoon Saskatchewan Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.787065"},{"key":"e_1_2_7_3_1","first-page":"41","volume-title":"Drug\u2010Induced Movement Disorders","author":"Friedman JH","year":"1992"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20806"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410160303"},{"key":"e_1_2_7_6_1","first-page":"10","article-title":"Drug\u2010induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs","volume":"11","author":"Marti Masso JF","year":"1996","journal-title":"Neurologia"},{"key":"e_1_2_7_7_1","first-page":"757","article-title":"Drug\u2010induced parkinsonian syndromes: a 10\u2010year experience at a regional center of pharmaco\u2010vigilance","volume":"150","author":"Llau ME","year":"1994","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.6.850"},{"volume-title":"Drug Induced Movement Disorders","year":"2005","author":"Friedman JH","key":"e_1_2_7_9_1"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470753217.ch4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510220042009"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10202"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20748"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.11.028"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ae7af1"},{"key":"e_1_2_7_16_1","first-page":"257","article-title":"Critical analysis of disability in Parkinson's disease","volume":"5","author":"Webster DD","year":"1968","journal-title":"Mod Treat"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00818.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0910-3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01485901"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.1.33"},{"key":"e_1_2_7_22_1","first-page":"124","volume-title":"Movement Disorders 2","author":"Jellinger K","year":"1987"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820070032005"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26209"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"P3.080","DOI":"10.1212\/WNL.82.10_supplement.P3.080","article-title":"Olfactory impairment and other features of Parkinson disease that predict persistent drug\u2010induced parkinsonism","volume":"82","author":"Morley J","year":"2014","journal-title":"Neurology"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2012.05.001"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.05.011"},{"key":"e_1_2_7_28_1","first-page":"175","volume-title":"Advances in Neurology","author":"Alvord EC","year":"1974"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/114.5.2283"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.1.30"},{"key":"e_1_2_7_31_1","first-page":"121","volume-title":"Drug Induced Movement Disorders","author":"Khot V","year":"2005"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.2.1.64"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006058000800507"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.133.8.940"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26467","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.26467","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:58:58Z","timestamp":1760950738000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,11]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1002\/mds.26467"],"URL":"https:\/\/doi.org\/10.1002\/mds.26467","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2015,12,11]]}}}